Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy.

about

Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy.

Item

http://www.wikidata.org/entity/Q41471527

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Clinical and therapeutic facto ...... herapy and radical cystectomy.

@en

type

Item

label

Clinical and therapeutic facto ...... herapy and radical cystectomy.

@en

prefLabel

Clinical and therapeutic facto ...... herapy and radical cystectomy.

@en

P1476

Clinical and therapeutic facto ...... herapy and radical cystectomy.

@en

P2093

Andrew J Stephenson

http://www.w3.org/2001/XMLSchema#string

Cesar E Ercole

http://www.w3.org/2001/XMLSchema#string

Colin P Dinney

http://www.w3.org/2001/XMLSchema#string

Evan Kovac

http://www.w3.org/2001/XMLSchema#string

Homayoun Zargar

http://www.w3.org/2001/XMLSchema#string

Jay B Shah

http://www.w3.org/2001/XMLSchema#string

Peter C Black

http://www.w3.org/2001/XMLSchema#string

Petros D Grivas

http://www.w3.org/2001/XMLSchema#string

Philippe E Spiess

http://www.w3.org/2001/XMLSchema#string

P2860

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer

A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment.

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.

Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling.

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.

A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience

Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

P2888

s00345-015-1667-4

P304

695-701

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00345-015-1667-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pranav Sharma

Kamran Zargar-Shoshtari

P577

2015-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1012929333

http://www.w3.org/2001/XMLSchema#string

P698

26286880

http://www.w3.org/2001/XMLSchema#string